Condition: Estrogen Receptor-Positive, HER2-Negative Advanced Breast Cancer · Sponsor: Hoffmann-La Roche
This is a Phase III, randomized, open-label multicenter study that will evaluate the efficacy and safety of giredestrant compared with fulvestrant, both in combination with the investigator's choice of a CDK4/6 inhibitor (palbociclib, ribociclib or abemaciclib), in participants with estrogen receptor-positive (ER+), human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer who have developed resistance to adjuvant endocrine therapy.
This description comes directly from the study's public registry record.
Reference Study ID Number: CO44657 https://forpatients.roche.com/ No attachments to email below. · 888-662-6728 (U.S. Only) · global-roche-genentech-trials@gene.com
Fastest response: use the inquiry form. https://www.gene.com/contact-us/submit-medical-inquiry
Always discuss trial participation with your own doctor first.
| Southern Cancer Center | Daphne, Alabama, United States | Recruiting |
| Sutter Auburn Faith Hospital | Auburn, California, United States | Withdrawn |
| La Hematology Oncology Medical Group | Glendale, California, United States | Recruiting |
| Marin Cancer Care Inc | Greenbrae, California, United States | Recruiting |
| Kaiser Permanente - Harbor City | Harbor City, California, United States | Recruiting |
| USC Norris Comprehensive Cancer Center | Los Angeles, California, United States | Recruiting |
| USC Norris Cancer Center | Newport Beach, California, United States | Recruiting |
| Sutter Medical Group, Roseville Clinic | Roseville, California, United States | Withdrawn |
| Sutter Health Medical Center | Sacramento, California, United States | Withdrawn |
| The Lundquist Institute for BioMedical Innovation at Harbor-UCLA Medical Cente | Torrance, California, United States | Recruiting |
| Rocky Mountain Cancer Centers | Littleton, Colorado, United States | Recruiting |
| Georgetown University Medical Center | Washington D.C., District of Columbia, United States | Recruiting |
+ 340 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06065748